Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C11H15N5O5
CAS Number:
Molecular Weight:
297.27
NACRES:
NA.77
UNSPSC Code:
12352200
InChI
1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10?/m1/s1
InChI key
IXOXBSCIXZEQEQ-KBNQYOMWSA-N
SMILES string
O[C@@H]1[C@@H](O[C@H](CO)[C@H]1O)N2C=NC3=C2N=C(N)N=C3OC
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
H2O: 5 mg/mL, clear (warmed)
storage temp.
2-8°C
Quality Level
Related Categories
Biochem/physiol Actions
Antineoplastic purine nucleoside analog used in T-cell acute lymphoblastic leukemia; pro-drug of Ara-G.
Nelarabine is an antineoplastic purine nucleoside analog used in T-cell acute lymphoblastic leukemia. It is a pro-drug of Ara-G, which is converted by cellular kinases to the active 5′-triphosphate, Ara-GTP. Incorporation of Ara-GTP into DNA leads to inhibition of DNA synthesis and apoptosis.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.
Marlise R Luskin et al.
British journal of haematology, 174(2), 332-334 (2015-09-26)
Stuart S Winter et al.
Pediatric blood & cancer, 62(7), 1176-1183 (2015-03-11)
Nelarabine has shown impressive single agent clinical activity in T-cell acute lymphoblastic leukemia (T-ALL), but has been associated with significant neurotoxicities in heavily pre-treated patients. We showed previously that it was safe to add nelarabine to a BFM-86 chemotherapy backbone
Larry W Buie et al.
Clinical therapeutics, 29(9), 1887-1899 (2007-11-24)
Nelarabine was approved by the US Food and Drug Administration (FDA) in October 2005 for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that has not responded to or has relapsed after treatment with at
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service